The tl;dr Pharmacy Journal Club: Voxelotor in Sickle Cell Disease (HOPE Trial)

It’s journal club time! If you've been paying attention to the news this week, you probably saw that Pfizer is voluntarily withdrawing Oxbryta (voxelotor) from the market due to safety concerns. This is an inherent (and unfortunate) risk for drugs approved under the FDA's accelerated approval pathway. Even though the drug itself bit the dust, this journal club still holds up!

Everything You Know about the P-Value is Wrong

The p-value and power are the holy grails of statistical significance, right? Let’s make sure you understand them (and how they can be exploited). This article may blow your mind. Journal club just got a whole lot more interesting…

How to be Awesome at Biostatistics and Literature Evaluation - Part IV

Finally! A practical, no nonsense guide to study design, bias, and literature evaluation.

The tl;dr Pharmacy Journal Club: Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS)

This is our first ever journal club, so let us know what you think about it! Shoot me a line at brandon@tldrpharmacy.com. If there's enough interest, we may do more of these journal clubs in the future.